Media Articles Related to Trelstar (Triptorelin)
Testosterone and Prostate Cancer: Looks Safe But . . . (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2016.09.24]
(MedPage Today) -- Data accumulating but not yet definitive
Data: May Be OK to Give 'T' to Men With Prostate Cancer
Source: Medscape Hematology-Oncology Headlines [2016.09.22]
The idea of prescribing testosterone to men with prostate cancer was once an anathema. But new data from a small patient cohort suggest that it may be okay.
Medscape Medical News
No Vasectomy-Prostate Cancer Link in Largest Study to Date
Source: Medscape Hematology-Oncology Headlines [2016.09.20]
Vasectomy is unlikely to meaningfully increase risk of developing or dying of prostate cancer, according to a new analysis of observational data.
Medscape Medical News
Vasectomy May Not Raise Prostate Cancer Risk After All
Source: MedicineNet Prostate Cancer Specialty [2016.09.20]
Title: Vasectomy May Not Raise Prostate Cancer Risk After All
Category: Health News
Created: 9/19/2016 12:00:00 AM
Last Editorial Review: 9/20/2016 12:00:00 AM
Study: Prostate Cancer-Vasectomy Link Weakens (CME/CE)
Source: MedPage Today Oncology/Hematology [2016.09.19]
(MedPage Today) -- Mortality, incidence, grade all unrelated to procedure
Published Studies Related to Trelstar (Triptorelin)
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. [2011.07.20]
CONTEXT: Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. OBJECTIVE: To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy... CONCLUSION: The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00311636.
A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. [2011.07]
PURPOSE: To compare the role of an aromatase inhibitor (letrozole) with a GnRH agonist (triptorelin) versus case control on the pregnancy rate and recurrence of symptoms and signs in patients with endometriosis... CONCLUSION: Pregnancy rate and endometriosis recurrence rate are comparable among the 3 groups.
Synchronization of ovulation and fertility in weaned sows treated with intravaginal triptorelin is influenced by timing of administration and follicle size. [2011.01.15]
A 100 mug dose of triptorelin was tested for synchronizing ovulation in sows. In Experiment 1, conducted in April through June, sows (n = 125) were assigned to Control (untreated), TG-96 (Triptorelin Gel (TG) given intravaginally at 96 h post-weaning), or TG-E (given intravaginally at estrus)... However, ovulation induction and timed AI success may benefit from an approach that ensures sows have adequate follicle development at time of treatment.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2010.01]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2009.01.08]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor may be advantageous for short-term management of women with myomas of any size who are to be managed transiently and who wish to avoid surgical intervention, specifically women with unexplained infertility having uterine myoma.
Clinical Trials Related to Trelstar (Triptorelin)
Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI [Recruiting]
To test whether long-acting Triptorelin on pituitary down-regulation can improve the
clinical pregnancy rate and reduces the incidence of ovarian hyperstimulation syndrome
(OHSS) in infertile high-risk patients with polycystic ovaries (PCOs) who underwent in vitro
fertilization (IVF) or Intracytoplasmic sperm injection
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer [Terminated]
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Chemoprotective drugs, such as triptorelin, may
protect normal ovarian cells from the side effects of chemotherapy.
PURPOSE: This randomized phase II trial is studying how well triptorelin works in preserving
ovarian function in premenopausal women who are receiving chemotherapy for early-stage
Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls [Active, not recruiting]
The aim of the study is to determine the specificity, sensitivity and diagnostic efficiency
of the Triptorelin Test in the assessment of CPP compared to GnRH test as gold standard.
Hypothesis: Aqueous Triptorelin Acetate is so efficient as GnRH to CPP assessment.
Study population are girls with suspicious clinical features of precocious puberty
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty [Completed]
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22. 5 mg
6-month formulation in 44 patients suffering from central precocious puberty. The null
hypothesis of the study is that the proportion of patients achieving luteinizing hormone
(LH) suppression to prepubertal levels at Month 6 is 80%.
Triptorelin for Ovary Protection in Childhood Onset Lupus [Completed]
The purpose of this study is to test the safety of triptorelin when used for the protection
of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for
systemic lupus erythematosus (SLE; lupus) and to see what effects (good or bad) it has on
patients. The study will be done with female patients who have been diagnosed with systemic
lupus erythematosus, are younger than 21 years of age, and require intravenous
cyclophosphamide to control the disease. Each patient will be in the study for
approximately 23 months, until 4 months after the intravenous cyclophosphamide treatment has
This study is currently being conducted at 3 sites across the United States and Brazil (Los
Angeles, Cincinnati and San Paulo Brazil). A total of 50 patients will participate in this
Each patient will be randomized (assigned) to one of 5 groups. Randomization means that
patients are put into a group completely by chance. It is like flipping a coin. Neither
the patient nor the study staff knows what group the patient is in. The patient has a 20%
chance of being placed in any group.
Funding Source: FDA OOPD and Watson Pharmaceuticals
Reports of Suspected Trelstar (Triptorelin) Side Effects
Hot Flush (3),
Initial Insomnia (2),
Vitamin D Deficiency (2),
Pruritus (2), more >>